Successful Use of Tocilizumab in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative Colitis

Table 1

Summary of medical treatment offered to patient.

	Duration	Reason for discontinuation
Drug for RA
Methotrexate (5 mg per week)	Max 15 months	Nausea
Methotrexate (7.5 mg to 10 mg per week)	Max 10 months	Nausea, malaise
Sulfasalazine	Less than 3 months	Mouth ulcers
Hydroxychloroquine	6 months	Taste disturbance
Leflunomide	30 months	Mouth and oesophageal ulcers
Azathioprine	3 months	Nausea, headache
Etanercept (monotherapy)	2 months	Facial flush, panic attacks
Infliximab (in combination with Methotrexate)	11 months	Facial flush, headache, depression
Drug  for UC
Asacol MR	4 months	Oral and pharyngeal mucositis
Treatments declined by patient
Ciclosporin	Worried about side effects
Other oral mesalazine preparations
Rituximab

Methotrexate was rechallenged alone or in combination on multiple occasions.